Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

surgery partners inc - SGRY

SGRY

Close Chg Chg %
13.56 -0.08 -0.59%

Closed Market

13.48

-0.08 (0.59%)

Volume: 1.03M

Last Updated:

Feb 9, 2026, 4:00 PM EDT

Trade Now

Company Overview: surgery partners inc - SGRY

SGRY Key Data

Open

$13.43

 Day Range

13.14 - 13.63

52 Week Range

13.14 - 26.16

 Market Cap

$1.75B

Shares Outstanding

129.34M

 Public Float

77.48M

Beta

1.98

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.36

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.29M

  

SGRY Performance

1 Week
 
 0.00%
 
1 Month
 
 -15.88%
 
3 Months
 
 -36.93%
 
1 Year
 
 -47.44%
 
5 Years
 
 -62.81%
 

SGRY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About surgery partners inc - SGRY

Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.

SGRY At a Glance

Surgery Partners, Inc.
340 Seven Springs Way
Brentwood, Tennessee 37027
Phone 1-615-234-5900 Revenue 3.11B
Industry Hospital/Nursing Management Net Income -168,100,000.00
Sector Health Services 2024 Sales Growth 13.524%
Fiscal Year-end 12 / 2025 Employees 15,000
View SEC Filings

SGRY Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.857
Price to Book Ratio 1.504
Price to Cash Flow Ratio 8.90
Enterprise Value to EBITDA 13.079
Enterprise Value to Sales 2.553
Total Debt to Enterprise Value 0.466

SGRY Efficiency

Revenue/Employee 207,620.00
Income Per Employee -11,206.667
Receivables Turnover 5.378
Total Asset Turnover 0.414

SGRY Liquidity

Current Ratio 1.793
Quick Ratio 1.651
Cash Ratio 0.432

SGRY Profitability

Gross Margin 19.041
Operating Margin 14.588
Pretax Margin 4.723
Net Margin -5.398
Return on Assets -2.237
Return on Equity -8.901
Return on Total Capital -3.06
Return on Invested Capital -3.268

SGRY Capital Structure

Total Debt to Total Equity 206.929
Total Debt to Total Capital 67.419
Total Debt to Total Assets 46.241
Long-Term Debt to Equity 198.972
Long-Term Debt to Total Capital 64.827
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Surgery Partners Inc - SGRY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.23B 2.54B 2.74B 3.11B
Sales Growth
+19.62% +14.12% +8.03% +13.52%
Cost of Goods Sold (COGS) incl D&A
1.83B 2.08B 2.21B 2.52B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
137.90M 149.60M 118.10M 153.50M
Depreciation
133.60M 143.20M 110.50M 144.80M
Amortization of Intangibles
4.30M 6.40M 7.60M 8.70M
COGS Growth
+16.34% +13.46% +6.48% +13.88%
Gross Income
392.60M 460.10M 529.40M 593.00M
Gross Income Growth
+37.75% +17.19% +15.06% +12.01%
Gross Profit Margin
+17.64% +18.12% +19.30% +19.04%
2021 2022 2023 2024 5-year trend
SG&A Expense
104.00M 102.20M 120.90M 138.70M
Research & Development
- - - -
-
Other SG&A
104.00M 102.20M 120.90M 138.70M
SGA Growth
+7.11% -1.73% +18.30% +14.72%
Other Operating Expense
- - - -
-
Unusual Expense
10.90M 31.10M 87.30M 104.40M
EBIT after Unusual Expense
277.70M 326.80M 321.20M 349.90M
Non Operating Income/Expense
(200.00K) 8.10M 41.50M 55.90M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
11.30M 12.50M 14.20M 19.50M
Interest Expense
196.30M 224.60M 227.70M 258.70M
Interest Expense Growth
+8.09% +14.42% +1.38% +13.61%
Gross Interest Expense
196.30M 224.60M 227.70M 258.70M
Interest Capitalized
- - - -
-
Pretax Income
81.20M 110.30M 135.00M 147.10M
Pretax Income Growth
+531.91% +35.84% +22.39% +8.96%
Pretax Margin
+3.65% +4.34% +4.92% +4.72%
Income Tax
10.50M 23.30M (300.00K) 134.60M
Income Tax - Current - Domestic
1.50M 1.50M 1.40M 3.10M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
9.00M 21.80M (1.70M) 131.50M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
11.30M 12.50M 14.20M 19.50M
Other After Tax Income (Expense)
- - - (10.30M)
-
Consolidated Net Income
60.40M 87.00M 135.30M 12.50M
Minority Interest Expense
141.60M 141.60M 147.20M 180.60M
Net Income
(81.20M) (54.60M) (11.90M) (168.10M)
Net Income Growth
+30.06% +32.76% +78.21% -1,312.61%
Net Margin Growth
-3.65% -2.15% -0.43% -5.40%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(81.20M) (54.60M) (11.90M) (168.10M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(81.20M) (54.60M) (11.90M) (168.10M)
EPS (Basic)
-1.1211 -0.5938 -0.0947 -1.3328
EPS (Basic) Growth
+64.86% +47.03% +84.05% -1,307.39%
Basic Shares Outstanding
72.43M 91.95M 125.61M 126.12M
EPS (Diluted)
-1.1211 -0.5938 -0.0947 -1.3328
EPS (Diluted) Growth
+64.86% +47.03% +84.05% -1,307.39%
Diluted Shares Outstanding
72.43M 91.95M 125.61M 126.12M
EBITDA
426.50M 507.50M 526.60M 607.80M
EBITDA Growth
+32.41% +18.99% +3.76% +15.42%
EBITDA Margin
+19.17% +19.99% +19.20% +19.52%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 25.455
Number of Ratings 12 Current Quarters Estimate -0.024
FY Report Date 03 / 2026 Current Year's Estimate 0.763
Last Quarter’s Earnings 0.33 Median PE on CY Estimate N/A
Year Ago Earnings 0.634 Next Fiscal Year Estimate 0.949
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 6 9 6
Mean Estimate -0.02 0.16 0.76 0.95
High Estimates 0.01 0.20 0.92 1.27
Low Estimate -0.12 0.14 0.29 0.49
Coefficient of Variance -197.75 14.39 24.58 29.87

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 9
OVERWEIGHT 0 0 0
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Surgery Partners Inc - SGRY

Date Name Shares Transaction Value
Mar 25, 2025 Trent Webb American Group President 57,380 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $31.95 per share 1,833,291.00
Mar 25, 2025 Trent Webb American Group President 60,330 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.7 per share 1,550,481.00
Mar 14, 2025 Jennifer B. Baldock Chief Admin & Dev Officer 236,659 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.97 per share 5,672,716.23
Mar 14, 2025 Marissa Brittenham Chief Strategy Officer 63,408 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.09 per share 1,527,498.72
Mar 14, 2025 David T. Doherty Chief Financial Officer 150,868 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.02 per share 3,623,849.36
Mar 14, 2025 Harrison R. Bane National Group President 126,520 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.16 per share 3,056,723.20
Mar 14, 2025 Danielle Burkhalter Chief Human Resources Officer 44,913 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.14 per share 1,084,199.82
Mar 14, 2025 William Trenton Webb American Group President 74,659 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $24.06 per share 1,796,295.54
Mar 7, 2025 J. Eric Evans Chief Executive Officer 644,731 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $23.8 per share 15,344,597.80
Mar 7, 2025 J. Eric Evans Chief Executive Officer 674,142 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $23.8 per share 16,044,579.60
Mar 7, 2025 Jennifer B. Baldock Chief Admin & Dev Officer 239,667 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $23.8 per share 5,704,074.60
Mar 7, 2025 Marissa Brittenham Chief Strategy Officer 66,564 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $23.8 per share 1,584,223.20
Mar 7, 2025 David T. Doherty Chief Financial Officer 157,601 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $23.8 per share 3,750,903.80
Mar 7, 2025 Harrison R. Bane National Group President 130,565 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $23.8 per share 3,107,447.00
Mar 7, 2025 Danielle Burkhalter Chief Human Resources Officer 46,153 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $23.8 per share 1,098,441.40
Mar 7, 2025 William Trenton Webb American Group President 76,716 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $23.8 per share 1,825,840.80

Surgery Partners Inc in the News